NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.77 +0.01 (+0.57%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.72▼$1.7950-Day Range$1.56▼$2.5252-Week Range$0.53▼$3.03Volume117,308 shsAverage Volume495,444 shsMarket Capitalization$151.59 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Compugen alerts: Email Address Compugen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside126.0% Upside$4.00 Price TargetShort InterestBearishDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.05 to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector770th out of 936 stocksBiological Products, Except Diagnostic Industry131st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has only been the subject of 1 research reports in the past 90 days.Read more about Compugen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Compugen has recently decreased by 0.57%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEN. Previous Next 3.1 News and Social Media Coverage News SentimentCompugen has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Compugen this week, compared to 1 article on an average week.Search Interest5 people have searched for CGEN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows1 people have added Compugen to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from $0.05 to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -9.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -9.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Compugen Stock (NASDAQ:CGEN)Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More CGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEN Stock News HeadlinesJuly 23 at 3:46 PM | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Compugen (CGEN)July 23 at 7:00 AM | prnewswire.comCompugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 17, 2024 | prnewswire.comCompugen to Present at Upcoming Antibody Industrial SymposiumMay 30, 2024 | prnewswire.comCompugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigMay 22, 2024 | markets.businessinsider.comCompugen’s Strategic Shift to PROC Program Merits a Buy RatingMay 22, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Compugen Ltd. (NASDAQ:CGEN) Price Target To US$5.00May 21, 2024 | msn.comCompugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 20, 2024 | finanznachrichten.deCompugen Ltd.: Compugen Reports First Quarter 2024 ResultsMay 20, 2024 | investorplace.comCGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024May 20, 2024 | prnewswire.comCompugen Reports First Quarter 2024 ResultsMay 17, 2024 | msn.comCompugen Q1 2024 Earnings PreviewMay 16, 2024 | prnewswire.comCompugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic PotentialMay 15, 2024 | finanznachrichten.deCompugen Ltd.: Compugen Appoints David Silberman as Chief Financial OfficerMay 15, 2024 | marketwatch.comCompugen Names David Silberman Chief Financial OfficerMay 15, 2024 | prnewswire.comCompugen Appoints David Silberman as Chief Financial OfficerMay 14, 2024 | stocknews.com3 Biotech Stocks to Monitor for May MovesSee More Headlines Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees70Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+126.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.19) Trailing P/E RatioN/A Forward P/E Ratio35.40 P/E GrowthN/ANet Income$-18,750,000.00 Net MarginsN/A Pretax Margin-21.44% Return on Equity-27.75% Return on Assets-17.57% Debt Debt-to-Equity RatioN/A Current Ratio4.29 Quick Ratio4.36 Sales & Book Value Annual Sales$33.46 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book2.33Miscellaneous Outstanding SharesN/AFree FloatN/AMarket Cap$151.59 million OptionableOptionable Beta2.60 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Anat Cohen-Dayag Ph.D. (Age 57)CEO, President & Director Comp: $796.52kDr. Zurit Levine Ph.D. (Age 56)Senior Vice President of Technology Innovation Comp: $345.7kDr. Pierre Ferre Ph.D. (Age 47)Vice President of Preclinical Development Comp: $415.1kMr. Alberto Sessa (Age 62)Chief Financial Officer Dr. Eran Ophir Ph.D. (Age 46)Chief Scientific Officer Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsMr. Eran Ben DorGeneral Counsel & Corporate SecretaryMs. Dorit Amitay (Age 56)Vice President of Human Resources Dr. Yaron Turpaz M.B.A. (Age 53)Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions Rivka SchwartzVice President Research and DiscoveryMore ExecutivesKey CompetitorsCoherus BioSciencesNASDAQ:CHRSInhibrxNASDAQ:INBXTCR2 TherapeuticsNASDAQ:TCRRBlack Diamond TherapeuticsNASDAQ:BDTXiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInstitutional OwnershipARK Investment Management LLCBought 48,979 shares on 7/26/2024Ownership: 0.000%Secure Asset Management LLCBought 41,345 shares on 7/24/2024Ownership: 0.000%Heron Bay Capital ManagementBought 12,547 shares on 5/14/2024Ownership: 0.014%Tocqueville Asset Management L.P.Sold 30,000 shares on 5/10/2024Ownership: 0.028%Oppenheimer & Co. Inc.Sold 5,000 shares on 5/7/2024Ownership: 0.018%View All Institutional Transactions CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.98 at the beginning of the year. Since then, CGEN stock has decreased by 10.6% and is now trading at $1.77. View the best growth stocks for 2024 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Monday, May, 20th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The biotechnology company had revenue of $2.56 million for the quarter, compared to analysts' expectations of $2.79 million. What is Anat Cohen-Dayag's approval rating as Compugen's CEO? 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Compugen's major shareholders? Top institutional shareholders of Compugen include ARK Investment Management LLC and Secure Asset Management LLC. How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV) and Inovio Pharmaceuticals (INO). This page (NASDAQ:CGEN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.